TY - JOUR
T1 - Prednimustine Therapy for Advanced Prostatic Cancer
AU - CATANE, R.
AU - KAUMAN, J. H.
AU - MADAJEWICZ, S.
AU - MITTELMAN, A.
AU - MURPHY, G. P.
PY - 1978/2
Y1 - 1978/2
N2 - Summary— 23 patients with advanced, hormonal‐resistant, prostatic cancer were treated with daily oral prednimustine — a combination of prednisolone and chlorambucil. 8 patients (35%) subjectively responded with disappearance of skeletal pain and improvement in appetite, weight and sense of well being. 3 patients had objective evidence of tumour regression. Clinical toxicity was moderate, and only occasional myelosuppression was encountered. The ease of administration and predictable toxicity of prednimustine make it a potentially useful agent, alone or in combination, for advanced prostatic cancer.
AB - Summary— 23 patients with advanced, hormonal‐resistant, prostatic cancer were treated with daily oral prednimustine — a combination of prednisolone and chlorambucil. 8 patients (35%) subjectively responded with disappearance of skeletal pain and improvement in appetite, weight and sense of well being. 3 patients had objective evidence of tumour regression. Clinical toxicity was moderate, and only occasional myelosuppression was encountered. The ease of administration and predictable toxicity of prednimustine make it a potentially useful agent, alone or in combination, for advanced prostatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=0017878946&partnerID=8YFLogxK
U2 - 10.1111/j.1464-410X.1978.tb02761.x
DO - 10.1111/j.1464-410X.1978.tb02761.x
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0017878946
SN - 0007-1331
VL - 50
SP - 29
EP - 32
JO - British Journal of Urology
JF - British Journal of Urology
IS - 1
ER -
